Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

A pharmaceutical contract development and manufacturing organization (CDMO) is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. Services offered by CDMO include, but are not limited to: pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials, late-stage clinical trial materials, formal stability, scale-up, registration batches and commercial production.

Market Overview:

The latest research study on the global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market finds that the global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market reached a value of USD 148788.52 million in 2022. It’s expected that the market will achieve USD 269537.93 million by 2028, exhibiting a CAGR of 10.41% during the forecast period.

The COVID-19 broke out on a global scale, and more than 17 million people were infected, undoubtedly having a profound impact on the global economy and politics. From retail catering, accommodation and tourism, transportation, cultural entertainment, and other industries, revenues have fallen sharply, to the slow resumption of work and production due to limited flow of people and logistics in manufacturing, real estate, construction, and construction, to telecommuting, online education, online medical The sudden emergence of technology companies such as fresh food logistics, the epidemic has brought different challenges and opportunities to various industries around the world, and these changes may profoundly affect the future development trend and competitive landscape of the industry. Overall, the impact of the COVID-19 epidemic on the CDMO industry has more advantages than disadvantages.

The outbreak of COVID-19 has inevitably affected the industry chain. The epidemic has affected all aspects of the pharmaceutical and biopharmaceutical industries, from drug development, clinical trials, supply, and manufacturing to supply chain logistics. Due to the limited inventory of raw materials, trade and logistics restrictions, CDMO services will be difficult to operate normally in the short term.
However, because drugs are an important tool for epidemic prevention and control, the overall demand for CDMO services is rising. Taking China WuXi AppTec as an example, the company's CDMO/CMO services will increase by 25.83% year-on-year in the first half of 2020. In 2020, the CMIC Group established a new subsidiary in Japan for process development and GMP production of antibody drugs using mammalian cell lines. Not only will industry demand increase significantly, but the industry will also receive more attention.

Region Overview:

North America dominated the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market in 2021, with a market share of 41.56%.

Company Overview:

Catalent Inc. is one of the major players operating in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market, holding a share of 2.83% in 2022.

Catalent Inc.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer health products. The Company's oral, injectable, and respiratory delivery technologies address the diversity of the pharmaceutical industry including small molecules, large molecule biologics, and consumer health products.

Lonza Group AG

Lonza AG produces organic fine chemicals, biocides, active ingredients, and biotechnology products. The Company offers custom chemical manufacturing and fermentation processing and manufactures its products for the life sciences, pharmaceuticals, food processing, and agricultural products industries.

Segmentation Overview:

By type, Biologics Drug Substance CDMO segment accounted for the largest share of market in 2021.

Form/Fill Drug Product CDMO

The term “formulation and fill” refers to the series of processing steps that are needed to turn a purified drug substance into the final dosage form, the finished product, for the market.

Biologics Drug Substance CDMO

Biologics are powerful medications that can be made of tiny components like sugars, proteins, or DNA or can be whole cells or tissues. Drug substance refers to the unformulated API (active pharmaceutical ingredient). The API has the therapeutic effect in the body as opposed to the excipients which assist with the delivery of the API. The chemical purity and physical state (crystal form) influence the quality and performance of a drug substance. This is especially important for water-insoluble drugs.

Application Overview:

The market's largest segment by application is the segment Preclinical, with a market share of 13.11% in 2021.

Preclinical

In drug development, preclinical development, also named preclinical studies and nonclinical studies, is a stage of research that begins before clinical trials can begin, and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals.

Phase I

Phase I trials aim to find the best dose of a new drug with the fewest side effects. Doctors start by giving very low doses of the drug to a few patients. Higher doses are given to other patients until side effects become too severe or the desired effect is seen. The drug may help patients, but Phase I trials are to test a drug’s safety. If a drug is found to be safe enough, it can be tested in phase II clinical trial.

Phase II

Phase II trials further assess safety as well as if a drug works. The drug is often tested among patients with a specific type of cancer. Phase II trials are done in larger groups of patients compared to Phase I trials. Often, new combinations of drugs are tested. Patients are closely watched to see if the drug works. However, the new drug is rarely compared to the current (standard-of-care) drug that is used.

Phase III

Phase III trials compare a new drug to the standard-of-care drug. These trials assess the side effects of each drug and which drug works better. Phase III clinical trials are often needed before the FDA will approve the use of a new drug for the general public.

Phase IV

Phase IV trials test new drugs approved by the FDA. This allows for better research on short-lived and long-lasting side effects and safety. Doctors can also learn more about how well the drug works and if it’s helpful when used with other treatments.

Key Companies in the global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market covered in Chapter 3:

Baxter Biopharma Solutions
CMIC Holdings Co. Ltd
Jubilant Life Sciences Ltd.
WuXi AppTec
Boehringer Ingelheim Group
Aenova Holding GmbH
Recipharm AB
Catalent Inc.
Pfizer CentreSource
Fareva
Famar SA
Patheon Inc.
Lonza Group
Siegfried Holding AG

In Chapter 4 and Chapter 14.2, on the basis of types, the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market from 2018 to 2029 is primarily split into:

Form/Fill Drug Product CDMO
Biologics Drug Substance CDMO
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market from 2018 to 2029 covers:

Pre-clinical
Phase I
Phase II
Phase III
Phase IV

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)